Cantor Fitzgerald reiterates Overweight rating on Aquestive stock at $15 target

Cantor Fitzgerald has reiterated its Overweight rating and $15 price target for Aquestive Therapeutics (AQST), citing significant upside potential driven by its Anaphylm product, a needle-less epinephrine alternative poised to disrupt the anaphylaxis treatment market. While AQST beat Q2 2025 EPS estimates at -$0.14, it missed revenue expectations at $10 million. The company recently secured an $85 million public offering and a $75 million strategic funding agreement with RTW Investments, contingent on Anaphylm's FDA approval, to support its commercialization, underscoring the product's perceived market opportunity and the company's strong liquidity.

Analysis

Aquestive Therapeutics (AQST) presents a compelling, high-risk/high-reward profile centered on its lead product candidate, Anaphylm. Cantor Fitzgerald's reiterated 'Overweight' rating and $15.00 price target underscore the significant perceived upside, driven by the potential for Anaphylm, a needle-less sublingual film, to disrupt the established epinephrine auto-injector market by offering superior portability and ease of administration. This positive outlook is bolstered by the company's strong liquidity, evidenced by a current ratio of 3.53, and recent capital infusions, including an $85 million public offering priced at $4.00 per share and a $75 million strategic funding agreement with RTW Investments. However, this narrative is tempered by mixed operational performance and significant dependencies. The company's Q2 2025 results showed a revenue miss of 11.66% against expectations, despite a 17.65% beat on EPS, suggesting potential weakness in its current revenue streams. Critically, the strategic funding from RTW is entirely contingent upon FDA approval for Anaphylm, making regulatory success the single most important binary event for the company's valuation and future commercial prospects. The structure of the RTW deal, which includes a tiered percentage of future U.S. net sales, also represents a future claim on the product's potential revenue.

Key Decisions for Investors

• Investors should recognize that an investment in AQST is primarily a speculative, event-driven play on the FDA's approval of Anaphylm, which represents the stock's main catalyst for realizing the $15 price target.
• While recent financing activities have strengthened the balance sheet for a potential commercial launch, the $85 million public offering at $4.00 per share introduces shareholder dilution and the RTW agreement will cede a portion of future Anaphylm revenues.
• Monitor the company's ability to reverse its recent top-line miss, as the 11.66% revenue shortfall in Q2 2025 indicates that execution risk extends beyond the primary regulatory hurdle for Anaphylm.